InvestorsHub Logo
Followers 3
Posts 607
Boards Moderated 0
Alias Born 06/07/2010

Re: Whosetosay post# 625

Friday, 06/25/2010 4:49:30 PM

Friday, June 25, 2010 4:49:30 PM

Post# of 80490
Form 8-K for ARIAD PHARMACEUTICALS INC


--------------------------------------------------------------------------------

25-Jun-2010

ARIAD also announced three other promotions or new positions: Frank G. Haluska, M.D., Ph.D. has been named Vice President, Clinical Research and Development and Chief Medical Officer; Edward M. Fitzgerald has been promoted to Executive Vice President and Chief Financial Officer; and Pierre F. Dodion, M.D., M.B.A. will move into the newly created position of Senior Vice President, Corporate Development.

No other material changes were made to the terms of the officers' employment. A copy of the press release announcing the promotions and new positions is attached hereto as Exhibit 99.1 and is incorporated by reference herein.





ITEM 5.07 Submission of Matters to a Vote of Security Holders.
On June 24, 2010, the Company held its 2010 Annual Meeting of Stockholders. Of 109,459,191 shares of common stock issued and outstanding and eligible to vote as of the record date of April 28, 2010, a quorum of 93,677,867 shares, or approximately 85.6 % of the eligible shares, was present in person or represented by proxy. The following actions were taken at such meeting:

1. Reelection of the following Class 1 Directors to serve until the 2013 annual meeting and until their successors are duly elected and qualified.


Voted For Withheld Authority Broker Non-Vote
Athanase Lavidas, Ph.D. 47,639,967 539,789 45,498,111
Massimo Radaelli, Ph.D. 46,557,931 1,621,825 45,498,111




After the meeting, Jay R. LaMarche, A. Collier Smyth, M.D. and Robert M. Whelan, Jr. continued to serve as Class 2 Directors for terms that expire at the 2011 annual meeting and until their successors are duly elected and qualified, and Harvey J. Berger, M.D. and Wayne Wilson continued to serve as Class 3 Directors for terms that expire at the 2012 annual meeting and until their successors are duly elected and qualified.

2. Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2010.

The voting results were 91,618,063 votes for, 1,724,990 votes against, 334,814 votes abstaining and no broker non-votes.

http://biz.yahoo.com/e/100625/aria8-k.html Lots of After hours activity!!

http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=ARIA&mkttype=after&symbol=RIMM&symbol=ARIA

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.